Updated phase 2 safety analysis of prevalence of infection, diarrhea, and bleeding with ibrutinib over time in previously treated mantle cell lymphoma Stilgenbauer, S., Rule, S., Wang, M. L., Martin, P., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J., Williams, M., Barrientos, J. C., Chmielowska, E., Radford, J., Truong, V., Chang, M., Beaupre, D. M., Goy, A., Blum, K. A. KARGER. 2014: 34–35

View details for Web of Science ID 000343816900074